AlzChem Group Past Earnings Performance

Past criteria checks 6/6

AlzChem Group has been growing earnings at an average annual rate of 19.4%, while the Chemicals industry saw earnings growing at 3.2% annually. Revenues have been growing at an average rate of 9.8% per year. AlzChem Group's return on equity is 26.1%, and it has net margins of 8.9%.

Key information

19.4%

Earnings growth rate

19.4%

EPS growth rate

Chemicals Industry Growth4.3%
Revenue growth rate9.8%
Return on equity26.1%
Net Margin8.9%
Next Earnings Update28 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How AlzChem Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0ACT Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24564501650
30 Jun 24555461610
31 Mar 24546391550
31 Dec 23546351490
30 Sep 23533301430
30 Jun 23554281400
31 Mar 23570301400
31 Dec 22550301390
30 Sep 22534291360
30 Jun 22487281350
31 Mar 22454271340
31 Dec 21429281330
30 Sep 21420271350
30 Jun 21406261330
31 Mar 21397231290
31 Dec 20386201290
30 Sep 20370161270
30 Jun 20389171270
31 Mar 20387171270
31 Dec 19385181250
30 Sep 19389191240
30 Jun 19380181220
31 Mar 19380201200
31 Dec 18383231180
30 Sep 18380221140
30 Jun 18398321230
31 Mar 18364211150
31 Dec 17361201140
30 Sep 17356221150
31 Dec 16333151110
30 Sep 16331121080
31 Dec 15329151060
31 Dec 1429814980
31 Dec 1330217930

Quality Earnings: 0ACT has high quality earnings.

Growing Profit Margin: 0ACT's current net profit margins (8.9%) are higher than last year (5.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0ACT's earnings have grown by 19.4% per year over the past 5 years.

Accelerating Growth: 0ACT's earnings growth over the past year (65.3%) exceeds its 5-year average (19.4% per year).

Earnings vs Industry: 0ACT earnings growth over the past year (65.3%) exceeded the Chemicals industry -13%.


Return on Equity

High ROE: 0ACT's Return on Equity (26.1%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 13:01
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AlzChem Group AG is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura Lopez PinedaBaader Helvea Equity Research
Konstantin WiechertBaader Helvea Equity Research
Knut WollerBaader Helvea Equity Research